Literature DB >> 8890099

Mutations in the mu heavy-chain gene in patients with agammaglobulinemia.

L Yel1, Y Minegishi, E Coustan-Smith, R H Buckley, H Trübel, L M Pachman, G R Kitchingman, D Campana, J Rohrer, M E Conley.   

Abstract

BACKGROUND: Most patients with congenital hypogammaglobulinemia and absent B cells are males with X-linked agammaglobulinemia, which is caused by mutations in the gene for Bruton's tyrosine kinase (Btk); however, there are females with a similar disorder who do not have mutations in this gene. We studied two families with autosomal recessive defects in B-cell development and patients with presumed X-linked agammaglobulinemia who did not have mutations in Btk.
METHODS: A series of candidate genes that encode proteins involved in B-cell signal-transduction pathways were analyzed by linkage studies and mutation screening.
RESULTS: Four different mutations were identified in the mu heavy-chain gene on chromosome 14. In one family, there was a homozygous 75-to-100-kb deletion that included D-region genes, J-region genes, and the mu constant-region gene. In a second family, there was a homozygous base-pair substitution in the alternative splice site of the mu heavy-chain gene. This mutation would inhibit production of the membrane form of the mu chain and produce an amino acid substitution in the secreted form. In addition, a patient previously thought to have X-linked agammaglobulinemia was found to have an amino acid substitution on one chromosome at an invariant cysteine that is required for the intrachain disulfide bond and, on the other chromosome, a large deletion that included the immunoglobulin locus.
CONCLUSIONS: Defects in the mu heavy-chain gene are a cause of agammaglobulinemia in humans. This implies that an intact membrane-bound mu chain is essential for B-cell development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890099     DOI: 10.1056/NEJM199611143352003

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  50 in total

1.  Igalpha: B all that you can B.

Authors:  L D Wang; M R Clark
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  Early B cell defects.

Authors:  H B Gaspar; M E Conley
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 3.  Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts.

Authors:  P P Sanna; D R Burton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

Review 5.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Prevalence of SAP gene defects in male patients diagnosed with common variable immunodeficiency.

Authors:  D Eastwood; K C Gilmour; K Nistala; C Meaney; H Chapel; Z Sherrell; A D Webster; E G Davies; A Jones; H B Gaspar
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 7.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

Review 8.  Clinical consequences of defects in B-cell development.

Authors:  Andre M Vale; Harry W Schroeder
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

9.  The IgE gene in primates exhibits extraordinary evolutionary diversity.

Authors:  Pheidias C Wu; Jiun-Bo Chen; Shoji Kawamura; Christian Roos; Stefan Merker; Chih-Chin Shih; Ban-Dar Hsu; Carmay Lim; Tse Wen Chang
Journal:  Immunogenetics       Date:  2011-11-10       Impact factor: 2.846

Review 10.  Primary B-cell immunodeficiencies.

Authors:  Tukisa Smith; Charlotte Cunningham-Rundles
Journal:  Hum Immunol       Date:  2018-10-22       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.